SAFETY AND IMMUNOGENICITY OF CONCOMITANT SEPARATE ADMINISTRATION OF MMRII, TETRAMUNE (WYETH LEDERLE DPT & HbOC) AND VARIVAX (OKA/MERCK VARICELLA VACCINE) VS. CONCOMITANT INJECTIONS OF MMRII AND TETRAMUNE• 660

Healthy children (N=609) 12 months to 23 months old were randomly assigned to one group(A) receiving MMRII, Tetramune and Varivax given separately and concomitantly and another group (B) receiving MMRII and Tetramune separately and concomitantly with Varivax given 6 weeks later. Subjects were followed for 42 days after each vaccination for local and systemic reactions. Serology was determined at day 42 for Group A and day 84 for Group B. No significant differences were noted between groups for local reactions, injection site rashes, fever≥102° F, or other systemic reactions as a group. There was a significant difference observed in GMTs for varicella(p=<0.001) as well as varicella gpELISA titers ≥5.0 (p≤0.013). PRP titers were similar in both groups. TableTable

Table 1

These data demonstrate statistical significant differences in varicella antibody levels when Varivax is administered concomitantly with MMR and Tetramune. Whether this is clinically important remains to be determined.(Funded by a Merck Research Laboratories Grant)

Table 2

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shinefield, H., Black, S., Morozumi, P. et al. SAFETY AND IMMUNOGENICITY OF CONCOMITANT SEPARATE ADMINISTRATION OF MMRII, TETRAMUNE (WYETH LEDERLE DPT & HbOC) AND VARIVAX (OKA/MERCK VARICELLA VACCINE) VS. CONCOMITANT INJECTIONS OF MMRII AND TETRAMUNE• 660. Pediatr Res 39, 113 (1996). https://doi.org/10.1203/00006450-199604001-00682

Download citation

Search